CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company’s oncology pipeline includes two programs in clinical development for cancer indications, such as aldoxorubicin and tamibarotene. Clinical Development Programs Aldoxorubicin Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is concentrated at the site of tumors. The company plans to initiate under an special protocol assessment (SPA) granted by the U.S. Food and Drug Administration (FDA) a pivotal Phase 3 trial of aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed following treatment with chemotherapy. The company completed a Phase 1b/2 clinical trial with aldoxorubicin in patients with advanced solid tumors who had either relapsed or failed to respond to their prior chemotherapy and presented favorable data at the American Society for Clinical Oncology Meeting in 2012. Bafetinib Bafetinib is an orally bioavailable, rationally-designed inhibitor of several Src kinases developed by the Japanese pharmaceutical company, Nippon Shinyaku, to overcome some of the limitations of Gleevec and other tyrosine kinase inhibitors in resistant chronic myelogenous leukemia. Tamibarotene Tamibarotene is an orally available, synthetic retinoid, rationally designed to overcome resistance and reduce the toxic side effects of differentiation therapy with all-trans retinoic acid, a component of the current first-line treatment for acute promyelocytic leukemia, or APL. Research and Development Expenditures for research and development activities related to continuing operations were $17.5 million for the year ended December 31, 2013. Patents and Proprietary Technology As of March 4, 2014, the company held rights in three granted U.S. patents, 53 granted foreign patents, 3 pending U.S. applications, and 7 pending foreign patent applications covering aldoxorubicin and related technologies. The company’s intellectual property holdings relating to aldoxorubicin and related technologies include an exclusive license from KTB Tumorforschungs GmbH to U.S. and foreign patents and patent applications. Patents and applications that cover pharmaceutical compositions of aldoxorubicin, processes for their production, and their use in treatment methods (e.g., cancer, viral diseases, autoimmune diseases, and acute or chronic inflammatory diseases) have an unextended patent term until between June 2020 and December 2034. As of March 4, 2014, the company’s exclusive license from Nippon Shinyaku to bafetinib and related technologies included 2 granted U.S., 30 granted foreign patents applications, and 3 pending foreign applications. Patents and applications that cover bafetinib, pharmaceutical compositions of bafetinib, and their use in treating leukemia have an unextended patent term until between 2020 and June 2023 or December 2024. Significant Events In October 2014, CytRx Corporation announced that it has commenced operations at its new discovery laboratory, located in Freiburg, Germany. History CytRx Corporation, a Delaware corporation, was founded in 1985. The company was incorporated in 1985.
cytrx corp (CYTR:NASDAQ CM)
11726 San Vicente Boulevard
Los Angeles, CA 90049
|No competitor information is available for CYTR.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact CYTRX CORP, please visit www.cytrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.